Hormonal Therapy for Prostate Cancer: Constructing Well-Defined Clinical Decisions
Speakers: Michael S. Cookson, MD, Professor and Chairman, Department of UrologyNeal D. Shore, MD, FACS, Immediate Past PresidentAlicia K. Morgans, MD, MPH, Associate Professor of Medicine
Duration: 60 minutes
Presented on: February 5, 2019
Michael S. Cookson, MD
Michael S. Cookson, MD
Professor and Chairman, Department of UrologyMichael S. Cookson, MD, is professor and chairman of the Department of Urology at the University of Oklahoma Health Sciences Center, and the Donald D. Albers Endowed Chair in Urology. He has devoted a significant portion of his academic career to managing patients with urologic cancers, with a strong emphasis on clinical guidelines, education, and evidence-based medicine. An accomplished researcher and lecturer, Dr Cookson is the author of 240 peer-reviewed journal publications, 33 textbook chapters, editor of 2 books in urology and urologic surgery, and is nationally recognized for his contributions to urologic oncology. He completed his urology residency at the University of Texas, San Antonio, and his urologic oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York.
Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS
Immediate Past PresidentNeal D. Shore, MD, FACS, is the medical director for the Carolina Urologic Research Center and practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr Shore has conducted more than 350 clinical trials that focus mainly on GU oncology, has served on the executive boards of the Society of Urologic Oncology, Bladder Cancer Advocacy Network and the Society of Urologic Oncology Clinical Trials Consortium, and is immediate past president of the Large Urology Group Practice Association. He is a founder for the CUSP Clinical Trials Consortium and DASHKO, large urology practices data registries. He has over 150 peer-reviewed publications, several book chapters, and is a peer reviewer for numerous high-impact medical journals. He earned his MD from Duke University Medical School and general surgery/urology residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center.
Alicia K. Morgans, MD, MPH
Alicia K. Morgans, MD, MPH
Associate Professor of MedicineAlicia Morgans, MD, MPH, is an associate professor of medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. She investigates the complications of systemic therapy for prostate cancer survivors. Her work includes the study of skeletal, cardiovascular, diabetic, and cognitive complications, as well as treatment decision-making in the metastatic prostate cancer population. She is the principal investigator for multiple therapeutic prostate cancer and bladder cancer clinical trials at Northwestern, and is an active member of the Eastern Oncology Cooperative Group and the Alliance for Clinical Trials in Oncology. Dr Morgans received her MD at the University of Pennsylvania Perelman School of Medicine in Philadelphia.
Optimal Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: Expert Analysis through Case Studies
LEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:
- Employ the latest NCCN and AUA clinical guidelines for prostate cancer
- Evaluate the benefits and challenges of available treatment modalities in order to effectively sequence them into treatment plans
AcknowledgementThis activity is supported by independent medical education grants from Bayer HealthCare Pharmaceuticals Inc, Sanofi Genzyme, and Tolmar.
Accreditation StatementThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and PlatformQ Heath Education. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statements
Live ActivityThe Annenberg Center for Health Sciences at Eisenhower designates this live activity a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring MaterialThe Annenberg Center for Health Sciences at Eisenhower designates this enduring material a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Date of Release/Expiration
Live ActivityWednesday, May 30, 2018 from 11:00am – 12:00pm EDT.
Enduring MaterialThe enduring material will be available from May 30, 2018 to November 30, 2018.
Target AudienceThis activity has been designed to meet the educational needs of urologists and genitourinary and medical oncologists, with a secondary audience of other health care professionals (internists, primary care physicians, physicians-in-training, oncology nurses, urology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with prostate cancer.
Estimated Time to CompleteThis activity consists of one session which should take approximately 1 hour to complete.
Method Of ParticipationThere are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.
Hardware/Software RequirementsParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FacutlyDaniel J. George, MD Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology Duke University School of Medicine Neal D. Shore, MD, FACS Medical Director Carolina Urologic Research Center
DISCLOSURE OF CONFLICTS OF INTERESTThe Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Financial DisclosuresDaniel J. George, MD Consulting Fees: Astellas, Axess Onc, Bayer, BMS, Exelixis, Innocrin, OncLive, J&J, Myovant, Pfizer, Sanofi Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Bayer, Exelixis, Sanofi Contracted Research: Acerta, AstraZeneca, Bayer, BMS, Dendreon, Exelixis, Innocrin, J&J, Millennium, Novartis, Pfizer, Sanofi Other: IDMC member, Acceleron Pharma Neal D. Shore, MD, FACS Consluting Fees: AbbVie, Amgen, AZ, BMS, Dendreon, Ferring, Genentech, Genomic Health, Inovio, Invitae, Janssen, Merck, Myriad, Nymox, Panacea, Pfizer, Roche, Sanofi-Genzyme, Tolmar Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: AbbVie, Amgen, AZ, BMS, Dendreon, Ferring, Genentech, Genomic Health, Inovio, Invitae, Janssen, Merck, Myriad, Nymox, Panacea, Pfizer, Roche, Sanofi-Genzyme, Tolmar Contracted Research: AbbVie, Amgen, AZ, BMS, Dendreon, Ferring, Genentech, Genomic Health, Inovio, Invitae, Janssen, Merck, Myriad, Nymox, Panacea, Pfizer, Roche, Sanofi-Genzyme, Tolmar The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. Charles E. Willis, Director of Continuing Education (Annenberg Center for Health Sciences at Eisenhower), consults for Pfizer, Inc. The following PlatformQ Health Education, LLC planners and managers, Hamsa Jaganathan, PhD, and Alissa Yost, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNAPPROVED/OFF LABEL USE
(if applicable):This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMERParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Contact InformationAccreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com. Techincal Support For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com..